Howard I. Scher, MD

home / authors / howard-i-scher-md

Articles

Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer

Diogo A. Bastos, MD;Carlos Dzik, MD;Dana Rathkopf, MD;Howard I. Scher, MD

August 15th 2014

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

September 1st 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

August 1st 2002

Combined-Modality Therapy for Bladder Cancer

John A. Mccaffrey, MB, MRCPI;Dean F. Bajorin, MD;Howard I. Scher, MD;George J. Bosl, MD

September 1st 1997

Radical cystectomy remains standard management for patients with locally advanced T2 through T4, N0, M0 transitional cell carcinoma of the urinary bladder.